255.30MMarket Cap-3107P/E (TTM)
3.230High3.080Low491.51KVolume3.200Open3.200Pre Close1.55MTurnover0.72%Turnover RatioLossP/E (Static)80.54MShares15.36052wk High0.60P/B217.39MFloat Cap3.08052wk Low--Dividend TTM68.58MShs Float65.250Historical High--Div YieldTTM4.69%Amplitude3.080Historical Low3.161Avg Price1Lot Size
Accolade Stock Forum
Accolade Announces Results for Fiscal Second Quarter 2025
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positiv...
• $Cytokinetics (CYTK.US)$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng (XPEV.US)$ +3.4% (June deliveries)
• $NIO Inc (NIO.US)$ +2.9% (June deliveries)
• $Bitfarms (BITF.US)$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade (ACCD.US)$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals (BCRX.US)$ +2.6% (presents new data demonstrating...
No comment yet